trans-1-Methoxy-penten-(1) | 72012-98-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans-1-Methoxy-penten-(1)
• 英文别名: (E)-1-methoxypent-1-ene
• CAS: 72012-98-7
• 化学式: C₆H₁₂O
• 分子量: 100.161
• InChiKey: KPEQNVUFSUUSAQ-AATRIKPKSA-N

物化性质

• 沸点：
  97.0±9.0 °C(Predicted)
• 密度：
  0.785±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1,1-二甲氧基戊烷 在 potassium hydrogensulfate 作用下， 生成 trans-1-Methoxy-penten-(1)
  参考文献：
  名称：

  Nerdel,F. et al., Justus Liebigs Annalen der Chemie, 1967, vol. 710, p. 36 - 58

  摘要：

  DOI：

文献信息

• [EN] USES OF SATL-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS<br/>[FR] UTILISATIONS D'INHIBITEURS DE KINASE INDUCTIBLE PAR UN SEL (SIK) POUR TRAITER L'OSTÉOPOROSE
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2018053373A1

  公开（公告）日：2018-03-22

  The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).

  本公开提供了使用盐诱导激酶（SIK）抑制剂治疗和/或预防骨质疏松症的方法。还提供了使用SIK抑制剂增加成骨细胞功能、增加成骨细胞数量、增加成骨细胞活性、抑制骨骼吸收、减少破骨细胞数量、抑制破骨细胞活性、增加骨骼质量、下调SOST基因表达和/或抑制硬化蛋白活性的方法。SIK抑制剂可以与Src抑制剂或CSF I R抑制剂结合使用。典型的SIK抑制剂包括公式：（I）、（II）、（III）、（IV）、（V）或（VI）的化合物。
• Modulators of LXR
  申请人：——

  公开号：US20030181420A1

  公开（公告）日：2003-09-25

  Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors. In certain embodiments, the compounds are N-substituted pyridones.

  提供了用于调节核受体活性的化合物、组合物和方法。具体来说，提供了用于调节核受体活性的杂环化合物，包括肝X受体（LXR）和孤儿核受体。在某些实施方式中，这些化合物是N-取代吡啶酮。
• Amino alcohol derivatives
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030236297A1

  公开（公告）日：2003-12-25

  Compounds of formula (I) which exhibit excellent immune suppression activity, pharmacologically acceptable salts thereof, esters thereof or other derivatives: 1 wherein R 1 and R 2 are a hydrogen atom, an amino protecting group; R 3 is a hydrogen atom, a hydroxy protecting group; R 4 is a lower alkyl group; n is an integer from 1 to 6; X is an ethylene group; Y is a C 1 -C 10 alkylene group, a C 1 -C 10 alkylene group substituted with 1 to 3 substituents selected from substituent group a and b; R 5 is an aryl group; R 6 and R 7 are a hydrogen atom, a group selected from substituent group a; with the proviso when R 5 is a hydrogen atom, Y is not a single bond or a straight chain C 1 -C 10 alkylene group.

  式（I）的化合物表现出优异的免疫抑制活性，其药理学上可接受的盐，酯或其他衍生物：其中R1和R2是氢原子，氨基保护基；R3是氢原子，羟基保护基；R4是较低的烷基基团；n是1到6之间的整数；X是乙烯基团；Y是C1-C10烷基基团，带有1到3个从取代基a和b中选择的取代基的C1-C10烷基基团；R5是芳基基团；R6和R7是氢原子，从取代基a中选择的基团；但是当R5是氢原子时，Y不是单键或直链的C1-C10烷基基团。
• [EN] CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CYCLO-OXYGÉNASE 2 ET LEURS UTILISATIONS
  申请人：BROAD INST INC

  公开号：WO2021050700A1

  公开（公告）日：2021-03-18

  The present disclosure describes compounds of the formula: (I), (II), (III), (IV), (V). The compounds described herein may be cyclooxygenase (COX) (e.g., cyclooxygenase 2 (COX2)) inhibitors. The compounds may be radiolabeled. The compounds (e.g., radiolabeled compounds) may be useful (e.g., as positron emission tomography (PET) imaging agents) for diagnosing a disease. The compounds may also be useful for treating or preventing a disease. The present disclosure also describes pharmaceutical compositions and kits including the compounds; and methods of using the compounds.

  本公开描述了以下式的化合物：(I)，(II)，(III)，(IV)，(V)。本文描述的化合物可能是环氧合酶（COX）（例如，环氧合酶2（COX2））抑制剂。这些化合物可能被放射标记。这些化合物（例如，放射标记化合物）可能用于诊断疾病（例如，作为正电子发射断层扫描（PET）成像剂）。这些化合物也可能用于治疗或预防疾病。本公开还描述了包括这些化合物的药物组合物和试剂盒；以及使用这些化合物的方法。
• Liquid crystalline compounds having a silane diyl group, liquid crystal compositions comprising the same and liquid crystal display devices
  申请人：CHISSO CORPORATION

  公开号：EP1160251A2

  公开（公告）日：2001-12-05

  Liquid crystalline compounds which have large dielectric anisotropy, high electrical insulation properties (high specific resistance or high voltage holding ratio), small temperature dependence, broad liquid crystal phase temperature range, excellent compatibility and low viscosity and which are represented by formula (1) A4 each independently represent 1,4-cyclohexylene,1,4-phenylene, etc.; R1 represents C1-C20 alkyl in which any methylene may be replaced by -O-, etc.; R2 represents halogen, cyano or C1-C10 alkyl in which at least one hydrogen is replaced by halogen; and at least one of Z1, Z2 and Z3 represents -SiH2CH2- or -CH2SiH2-. Further, liquid crystal compositions comprising at least one liquid crystalline compound of formula (1) and liquid crystal display devices composed of the compositions, which can exhibit low threshold voltage, high electrical insulation properties and low viscosity.

  具有大介电各向异性、高电绝缘性能（高比电阻或高耐电压比）、温度依赖性小、液晶相温度范围广、优异的相容性和低粘度的液晶化合物，其化学式为（1）中A4分别独立表示1,4-环己烯基、1,4-苯基等；R1表示C1-C20烷基，其中任何亚甲基可能被-O-等取代；R2表示卤素、氰基或C1-C10烷基，其中至少有一个氢原子被卤素取代；Z1、Z2和Z3中至少有一个表示-SiH2CH2-或-CH2SiH2-。此外，液晶化合物至少包括化学式（1）中的一种液晶化合物的液晶组合物和由该组合物组成的液晶显示器件，可表现出低阈值电压、高电绝缘性能和低粘度。